Search Within

Daniel C Danila

  1. "Hematologic Malignancies, Division of"
Formats
  1. Meeting Abstract (26)
  2. Journal Article (22)
Groups
  1. Department of Medicine (48)
  2. Genitourinary Oncology Service (48)
  3. Hematologic Malignancies, Division of (48)
  4. Solid Tumor Oncology Division (48)
  5. GSK Faculty (34)
  6. Human Oncology and Pathogenesis Program (27)

More Groups

People
  1. Howard Scher (43)
  2. Susan Slovin (39)
  3. Michael Morris (38)
  4. Dana Rathkopf (37)
  5. Karen Autio (19)
  6. Wassim Abida (16)

More People

Years
  1. 2025 (1)
  2. 2024 (1)
  3. 2023 (2)
  4. 2022 (3)
  5. 2021 (2)
  6. 2020 (5)

More Years

Publications
  1. Journal of Clinical Oncology (27)
  2. Clinical Cancer Research (3)
  3. JCO Precision Oncology (3)
  4. Clinical Genitourinary Cancer (2)
  5. European Urology (2)
  6. Annals of Oncology (1)

More Publications

Publishers
  1. American Society of Clinical Oncology (30)
  2. American Association for Cancer Research (4)
  3. Elsevier Science, Inc. (3)
  4. Elsevier BV (2)
  5. Elsevier Inc. (2)
  6. American Medical Association (1)

More Publishers

Results (48)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Clinical, imaging, and technical factors associated with successful genomic profiling of bone biopsy tissue in prostate cancer
    Journal Article

    Ridouani, F.; Vargas, H. A.; Holzwanger, D. J.; Schòˆder, H.; Waters, E.; Petre, E. N.; Martin, A.; Satagopan, J.; Gonen, M.; Autio, K. A.; more...
    European Urology Oncology (2025)

    Fulltext@MSK | Save
  • Microsatellite instability, tumor mutational burden, and response to immune checkpoint blockade in patients with prostate cancer
    Journal Article

    Lenis, A. T.; Ravichandran, V.; Brown, S.; Alam, S. M.; Katims, A.; Truong, H.; Reisz, P. A.; Vasselman, S.; Nweji, B.; Autio, K. A.; more...
    Clinical Cancer Research (2024)

    Fulltext@MSK | Save
  • Evaluating immune-related adverse events using PRO-CTCAE in a phase II study of ipilimumab for hormone-sensitive prostate cancer
    Journal Article

    Vargas P. de Almeida, D.; Anderson, J. M.; Danila, D. C.; Morris, M. J.; Slovin, S. F.; Abida, W.; Cohn, E. D.; Baser, R. E.; Scher, H. I.; Autio, K. A.
    Journal of Immunotherapy and Precision Oncology (2023)

    Fulltext@MSK | Save
  • Gene-based confirmatory germline testing following tumor-only sequencing of prostate cancer
    Journal Article

    Truong, H.; Breen, K.; Nandakumar, S.; Sjoberg, D. D.; Kemel, Y.; Mehta, N.; Lenis, A. T.; Reisz, P. A.; Carruthers, J.; Benfante, N.; more...
    European Urology (2023)

    Fulltext@MSK | Save
  • Clinical annotations for prostate cancer research: Defining data elements, creating a reproducible analytical pipeline, and assessing data quality
    Journal Article

    Keegan, N. M.; Vasselman, S. E.; Barnett, E. S.; Nweji, B.; Carbone, E. A.; Blum, A.; Morris, M. J.; Rathkopf, D. E.; Slovin, S. F.; Danila, D. C.; more...
    Prostate (2022)

    Fulltext@MSK | Save
  • Clinical annotations for prostate cancer research: Defining data elements, creating a reproducible analytical pipeline, and assessing data quality
    Meeting Abstract

    Keegan, N. M.; Vasselman, S. E.; Barnett, E.; Nweji, B.; Carbone, E.; Blum, A.; Morris, M. J.; Rathkopf, D. E.; Slovin, S. F.; Danila, D. C.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Differences in prostate cancer genomes by self-reported race: Contributions of genetic ancestry, modifiable cancer risk factors, and clinical factors
    Journal Article

    Stopsack, K. H.; Nandakumar, S.; Arora, K.; Nguyen, B.; Vasselman, S. E.; Nweji, B.; McBride, S. M.; Morris, M. J.; Rathkopf, D. E.; Slovin, S. F.; more...
    Clinical Cancer Research (2022)

    Fulltext@MSK | Save
  • Randomized phase 2 trial of abiraterone acetate plus prednisone, degarelix, or the combination in men with biochemically recurrent prostate cancer after radical prostatectomy
    Journal Article

    Autio, K. A.; Antonarakis, E. S.; Mayer, T. M.; Shevrin, D. H.; Stein, M. N.; Vaishampayan, U. N.; Morris, M. J.; Slovin, S. F.; Heath, E. I.; Tagawa, S. T.; more...
    European Urology Open Science (2021)

    Fulltext@MSK | Save
  • Immunomodulatory activity of a colony-stimulating factor-1 receptor inhibitor in patients with advanced refractory breast or prostate cancer: A phase I study
    Journal Article

    Autio, K. A.; Klebanoff, C. A.; Schaer, D.; Kauh, J. S. W.; Slovin, S. F.; Adamow, M.; Blinder, V. S.; Brahmachary, M.; Carlsen, M.; Comen, E.; more...
    Clinical Cancer Research (2021)

    Fulltext@MSK | Save
  • Evaluation of immune-related adverse events (irAE): Utilizing the patient-reported outcomes of the common terminology criteria for adverse events (PRO-CTCAE) in a phase II study of ipilimumab (ipi) in men with castration-sensitive prostate cancer (CSPC)
    Meeting Abstract

    Vargas Pivato de Almeida, D.; Anderson, J.; Danila, D. C.; Morris, M. J.; Slovin, S. F.; Abida, W.; Dayan, E. S.; Curley, T.; Arauz, G.; Baser, R. E.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save